Literature DB >> 4353387

Detection of circulating hepatoma D23 antigen and immune complexes in tumour bearer serum.

R W Baldwin, J G Bowen, M R Price.   

Abstract

Serum from rats bearing progressively growing aminoazo dye-induced rat hepatomata has been fractionated by Sephadex G150 gel filtration chromatography and isolated fractions have been examined by indirect membrane immunofluorescence techniques to detect tumour specific antigen and antibody. Hepatoma D23-specific antigenic activity was associated with material (of approximate molecular weight <150,000) isolated in the included volume of the gel at pH 7·3. The fraction excluded from the gel (of approximate molecular weight >150,000) was adjusted to pH 3·0 and further separated by Sephadex G150 gel filtration chromatography at pH 3·0 into gel included and excluded fractions. Hepatoma D23 specific antibody, demonstrable by membrane immunofluorescence staining of hepatoma D23 cells, was found to be eluted in the excluded volume and specific antigenic activity was retarded into the included volume of the gel. These results indicate that hepatoma D23 bearer serum contains free circulating tumour specific antigen in excess, together with specific immune complexes. The presence of these factors in tumour bearer serum is discussed in terms of "blocking" phenomena whereby serum factors may protect tumour cells from sensitized lymphocyte cytotoxic attack.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4353387      PMCID: PMC2009068          DOI: 10.1038/bjc.1973.66

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Fractionation of plasma membrane-associated tumor-specific antigen from an aminoazo dye-induced rat hepatoma.

Authors:  R W Baldwin; J R Harris; M R Price
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

2.  Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes.

Authors:  R W Baldwin; M R Price; R A Robins
Journal:  Nat New Biol       Date:  1972-08-09

3.  Solubilization of tumour-specific antigen from plasma membrane of an aminoazo-dye-induced rat hepatoma.

Authors:  R W Baldwin; D Glaves
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

4.  Cellular and humoral immunity to rat hepatoma-specific antigens correlated with tumour status.

Authors:  R W Baldwin; M J Embleton; R A Robins
Journal:  Int J Cancer       Date:  1973-01-15       Impact factor: 7.396

5.  Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas.

Authors:  I Hellström; K E Hellström
Journal:  Int J Cancer       Date:  1969-09-15       Impact factor: 7.396

6.  Elution of "blocking factors" from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes.

Authors:  H O Sjögren; I Hellström; S C Bansal; G A Warner; K E Hellström
Journal:  Int J Cancer       Date:  1972-03-15       Impact factor: 7.396

7.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

Authors:  H O Sjögren; I Hellström; S C Bansal; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

8.  Demonstration of tumour-specific humoral antibody against aminoazo dye-induced rat hepatomata.

Authors:  R W Baldwin; C R Barker
Journal:  Br J Cancer       Date:  1967-12       Impact factor: 7.640

9.  Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen.

Authors:  G A Currie; C Basham
Journal:  Br J Cancer       Date:  1972-12       Impact factor: 7.640

10.  The presence of tumour-specific membrane antigen in the serum of rats with chemically induced sarcomata.

Authors:  D M Thomson; K Steele; P Alexander
Journal:  Br J Cancer       Date:  1973-01       Impact factor: 7.640

  10 in total
  12 in total

1.  Use of the defined antigen substrate spheres system as a model for analysing possible mechanisms of inhibition-blockade of anti-tumour lymphocytotoxicity.

Authors:  N Matthews; T de Kretser; R C Nairn
Journal:  Immunology       Date:  1975-06       Impact factor: 7.397

2.  Characterization of human malignant melanoma cell lines. VII. Glycoprotein synthesis and shedding as revealed by [3H]glucosamine labeling.

Authors:  A F Rahman; S K Liao; P B Dent
Journal:  In Vitro       Date:  1977-09

3.  Immune complexes with antiglobulin activity in sera of Moloney sarcoma-bearing rats.

Authors:  J R Balint
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

4.  Consistent fluctuations in quantities of circulating immune complexes during progressive and regressive phases of tumor growth.

Authors:  J C Jennette
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

5.  Immunological escape mechanism in spontaneously metastasizing mammary tumors.

Authors:  U Kim; A Baumler; C Carruthers; K Bielat
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

6.  Tumour markers with unknown functions in gynaecological neoplasia.

Authors:  M R Price; P J McLaughlin; R A Robins; R W Baldwin; D Vasey; E M Symonds
Journal:  Arch Gynecol       Date:  1980

7.  Anti-leukaemia activity as a bystander effect of graft-versus-host reactions.

Authors:  P R Johnson; P Hersey
Journal:  Br J Cancer       Date:  1976-04       Impact factor: 7.640

8.  Tumour-associated antigens reacting with cytotoxic antibodies in serum of hepatoma-bearing rats.

Authors:  P Lando; K Berzins; J Gabriel; P Larsson; P Perlmann
Journal:  Br J Cancer       Date:  1981-10       Impact factor: 7.640

9.  Radioimmunoassay of tumour specific transplantation antigen of a chemically induced rat sarcoma: circulating soluble tumour antigen in tumour bearers.

Authors:  D M Thomson; V Sellens; S Eccles; P Alexander
Journal:  Br J Cancer       Date:  1973-11       Impact factor: 7.640

10.  Immunogenic properties of rat hepatoma subcellular fractions.

Authors:  M R Price; R W Baldwin
Journal:  Br J Cancer       Date:  1974-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.